<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002381</url>
  </required_header>
  <id_info>
    <org_study_id>200F</org_study_id>
    <secondary_id>1100.1224</secondary_id>
    <nct_id>NCT00002381</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine</brief_title>
  <official_title>An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1 Infected Adults Treated With Stavudine [d4T] (Zerit)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the potential effects of 28 days of nevirapine treatment on the steady-state&#xD;
      pharmacokinetics of nelfinavir and of stavudine (d4T), and to further evaluate the&#xD;
      pharmacokinetics of nevirapine in combination with nelfinavir, and d4T compared to the&#xD;
      historical controls treated with nevirapine but without nelfinavir or d4T. To determine the&#xD;
      efficacy of long-term combination therapy of nevirapine, nelfinavir and d4T on viral load in&#xD;
      patients who are non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease&#xD;
      inhibitor naive, and have &lt;= 6 months prior d4T exposure at the time of screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label study in patients with HIV-1 infection who are naive to treatment&#xD;
      with NNRTI and protease inhibitor classes of antiretroviral drugs and have &lt;= 6 months prior&#xD;
      exposure to d4T at the time of screening. Part I of this trial is an investigation of&#xD;
      potential pharmacokinetic interaction between nevirapine and nelfinavir in HIV-1-infected&#xD;
      adults treated with d4T. Part II is an investigation of the long-term antiviral activity of&#xD;
      the combination of nevirapine and nelfinavir on viral load as measured by HIV-1 RNA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4+ cell count &gt;= 100 cells/mm3.&#xD;
&#xD;
          -  Plasma HIV-1 RNA &gt;= 5000 copies/ml.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Previous antiretroviral therapy with zidovudine, lamivudine, didanosine, and&#xD;
        dideoxycytidine.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Malabsorption, severe chronic diarrhea, or the inability to maintain adequate oral&#xD;
             intake.&#xD;
&#xD;
          -  Undergoing treatment for an active infection.&#xD;
&#xD;
          -  Hepatic insufficiency due to cirrhosis.&#xD;
&#xD;
          -  Renal insufficiency.&#xD;
&#xD;
             1. Systemic treatment with corticosteroids or drugs known to be hepatic enzyme&#xD;
             inducers or inhibitors within 14 days of entry. Substances in these categories&#xD;
             include:&#xD;
&#xD;
          -  macrolide antibiotics (erythromycin, clarithromycin, azithromycin, dirithromycin),&#xD;
             azole antifungals (ketoconazole, fluconazole, itraconazole), rifampin, rifabutin, and&#xD;
             phenytoin.&#xD;
&#xD;
          -  Previous exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as&#xD;
             delavirdine, loviride, DMP 266, or nevirapine and/or protease inhibitors (PI) such as&#xD;
             saquinavir, ritonavir, indinavir, and nelfinavir.&#xD;
&#xD;
          -  &gt; 6 months previous exposure to d4T.&#xD;
&#xD;
          -  Investigational drugs within 30 days of first dose of study medication.&#xD;
&#xD;
          -  Any antineoplastic agent within 12 weeks before starting study medication.&#xD;
&#xD;
        Radiotherapy, other than local skin radiotherapy treatment, within 12 weeks prior to study.&#xD;
&#xD;
        1. History of intravenous drug abuse or alcohol or substance abuse considered by the&#xD;
        Investigator and BIPI Medical Monitor to be a significant impairment to health and&#xD;
        compliance.&#xD;
&#xD;
          -  Heavy smokers (e.g., &gt; 20 cigarettes per day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Francis Mem Hosp / HIV Care Unit</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Med Ctr</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Stavudine</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

